Search clinical trials for: Metastatic NSCLC

Total 17242 results

Intima Bioscience, Inc.

Not yet recruiting

CISH Inactivated TILs in the Treatment of NSCLC (CheckCell-2)

Carcinoma, Non-Small-Cell Lung | Adenocarcinoma of Lung | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Large Cell Lung Cancer

United States
RedCloud Bio
R&G Pharma Studies Co.,Ltd.

Recruiting

H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC

Non-small Cell Lung Cancer

China
Duke University
Regeneron Pharmaceuticals

Recruiting

PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

Non-small Cell Lung Cancer (NSCLC)

United States
Fondazione IRCCS Istituto Nazionale dei Tumori,...
University of Chicago; Shaare Zedek Medical Center; Vall d'Hebron Institute of... and other collaborators

Recruiting

I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy

Lung Cancer Metastatic | Non Small Cell Lung Cancer | Lung Adenocarcinoma | Lung Cancer, Nonsmall Cell

United States, Spain, Greece, Israel
Elephas
Hoosier Cancer Research Network

Recruiting

Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (CYBRID-02)

Clear Cell Renal Cell Carcinoma | Colorectal Cancer | Non Small Cell Lung Cancer | Endometrial Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Cutaneous Melanoma

United States
Shanghai EpimAb Biotherapeutics Co., Ltd.
Labcorp Corporation of America Holdings, Inc

Not yet recruiting

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma | EGFR Mutation-Related Tumors

United States, China
Peking University Third Hospital

Not yet recruiting

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer
Navire Pharma Inc., a BridgeBio company
Amgen

Recruiting

SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation (Argonaut)

Non Small Cell Lung Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Metastatic NSCLC

Spain, Australia, France, Denmark, Greece, Italy, Netherlands
Elephas
Beaufort CRO

Recruiting

Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (CYBRID-01)

NSCLC | Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Metastatic NSCLC - Non-Small Cell Lung Cancer

United States
AP Biosciences Inc.

Not yet recruiting

A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies (APT-CUBE)

Esophageal Squamous Cell Carcinoma (ESCC) | Locally Advanced or Metastatic Solid Tumors | Non Small Cell Lung Cancer (NSCLC) | Head and Neck Squamous Cell Carcinoma (HNSCC)
Sichuan Cancer Hospital and Research Institute

Recruiting

Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer (IMCORT-2)

Non-small Cell Lung Cancer Metastatic

China
Allist Pharmaceuticals, Inc.

Not yet recruiting

Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion

NSCLC
Revolution Medicines, Inc.

Recruiting

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Advanced Solid Tumor | Pancreatic Ductal Adenocarcinoma | Non-Small Cell Lung Cancer (NSCLC) | Colorectal Cancer (CRC)

United States, Italy, Spain, Malaysia, Korea, Republic of, France, Australia, Thailand, Taiwan, Poland, Singapore, Czechia, Serbia
AstraZeneca
Parexel

Recruiting

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY)

Advanced or Metastatic Non-Small Cell Lung Cancer

China, Netherlands, Korea, Republic of, Italy, Spain, Canada, Hungary, Japan, Argentina, France, United States, Taiwan, Poland, Serbia, United Kingdom, Hong Kong, Brazil, Germany, Belgium, Romania, India, Ireland, Australia
OBI Pharma, Inc

Recruiting

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (EGFR)

Non-small Cell Lung Cancer

Taiwan
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Hase 1/2 Study of HS-10375 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

Advanced or Metastatic NSCLC

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

Non Small Cell Lung Cancer

China
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Minimal Residual Disease | NSCLC Stage IV | Nsclc | Metastatic Non Small Cell Lung Cancer

United States
Fudan University

Not yet recruiting

Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer (BETTER)

Non-small Cell Lung Cancer Metastatic
iTeos Belgium SA

Recruiting

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Metastatic NSCLC | Stage III NSCLC

United States, Belgium, Spain, Switzerland, Italy, France, Canada, Poland, Czechia
Nuvalent Inc.

Recruiting

A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Metastatic Solid Tumor | Locally Advanced Solid Tumor

United States, Australia, Taiwan, Spain, United Kingdom, France, Korea, Republic of, Canada, Singapore
TYK Medicines, Inc

Recruiting

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

NSCLC | EGFR Activating Mutation

China
Revolution Medicines, Inc.

Recruiting

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Advanced Solid Tumors | Non-small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC)

United States
Guangzhou University of Traditional Chinese Medicine

Recruiting

Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients

Non-small Cell Lung Cancer

China
Verastem, Inc.
Mirati Therapeutics Inc.

Recruiting

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients (RAMP204)

Non Small Cell Lung Cancer | Metastatic Cancer | Advanced Cancer | Malignant Neoplasm of Lung | Malignant Neoplastic Disease | KRAS Activating Mutation

United States
ArriVent BioPharma, Inc.

Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768I

United States, Australia, Spain, United Kingdom, France, Italy, China, Korea, Republic of, Canada, Japan, Netherlands
Iovance Biotherapeutics, Inc.

Recruiting

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Metastatic Melanoma | Unresectable Melanoma | Stage IV Non-small Cell Lung Cancer | Stage III Non-small Cell Lung Cancer

United States
Qianfoshan Hospital

Recruiting

Patient's Whole Process Follow-up Management(HOPE-1) (HOPE-1)

Metastatic NSCLC | Locally Advanced Non-Small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors

Metastatic Cancer | Malignant Neoplasms

China
Orano Med LLC

Recruiting

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Cervical Cancer | Breast Cancer | NSCLC | Colon Cancer | Prostate Cancer Metastatic | Cutaneous Melanoma

United States
Tata Memorial Hospital

Recruiting

Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC (TARGET-02)

Oligometastatic Disease | Metastatic Non Small Cell Lung Cancer

India
GlaxoSmithKline

Recruiting

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Neoplasms

United States, Australia, Spain, Canada, France, Korea, Republic of, United Kingdom, Japan, China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

Non-small Cell Lung Cancer

China
Lyell Immunopharma, Inc.

Recruiting

A Study to Investigate LYL797 in Adults With Solid Tumors

Advanced Breast Cancer | NSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Recurrent Breast Cancer | TNBC - Triple-Negative Breast Cancer | Relapsed Cancer | NSCLC, Recurrent | Recurrent... and other conditions

United States
Aulos Bioscience, Inc.

Recruiting

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Metastatic Cancer | Advanced Solid Tumor

Australia, United States
Clinica Universidad de Navarra, Universidad de...
Highlight Therapeutics

Recruiting

Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC (Noelia)

Non-Small Cell Lung Cancer Metastatic

Spain
AstraZeneca

Recruiting

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (SAFFRON)

Carcinoma | Non-Small-Cell Lung

China, Israel, Spain, United States, Canada, Italy, Korea, Republic of, Belgium, Bulgaria, Vietnam, Japan, United Kingdom, Brazil, France, Philippines, Taiwan, Thailand, Germany, Poland, Austria, Greece, Turkey, Argentina, Hong Kong, Chile and more
Black Diamond Therapeutics, Inc.

Recruiting

Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Non-Small Cell Lung Cancer | NSCLC | Metastatic Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma | EGF-R Positive Non-Small Cell Lung Cancer | Advanced Lung Carcinoma | EGFR-TKI Resistant Mutation | Advanced Non-Small Cell Squamous Lung Cancer | Epidermal Growth Factor Receptor C797S | Epidermal...

Korea, Republic of, United States
Fudan University
Allist Pharmaceuticals, Inc.

Recruiting

Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)

Non-Small-Cell Lung Cancer

China
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction (DIAL)

Metastatic NSCLC

France
National University Hospital, Singapore
Bristol-Myers Squibb; Adagene Inc; Singapore Translational Cancer Consortium

Recruiting

A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC (ADIVO Lung)

Metastatic Non Small Cell Lung Cancer

Singapore
GeneScience Pharmaceuticals Co., Ltd.

Recruiting

A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC

Metastatic Non-Small Cell Lung Cancer

China
Peter MacCallum Cancer Centre, Australia

Recruiting

PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer - A Pilot Study (PRIME_LUNG)

NSCLC

Australia
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

Metastatic Non Small Cell Lung Cancer

United States, China, Belgium, Portugal, Japan, Taiwan, France, United Kingdom, Spain, Hungary, Thailand, Germany, Italy, Switzerland, Hong Kong, Korea, Republic of, Australia, Mexico, Brazil, Netherlands, Romania, Argentina, Chile, G... and more
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.

Recruiting

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor

Locally Advanced or Metastatic Solid Tumor

China
BioAtla, Inc.

Recruiting

A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors

Melanoma | Carcinoma | Renal Cell Carcinoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | NSCLC | Cervical Carcinoma | Urothelial Carcinoma | Solid Tumor, Adult

United States, Australia
DualityBio Inc.

Recruiting

A Study of DB-1303 in Advanced/Metastatic Solid Tumors

HER2-positive Advanced Solid Tumor

China, United States, Australia, Puerto Rico
Scott Antonia

Recruiting

A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC (TOP2101)

Lung Cancer Metastatic

United States
Shanghai Miracogen Inc.

Not yet recruiting

A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

Non-small- Cell Lung Cancer (NSCLC)

China
Novartis Pharmaceuticals

Recruiting

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02)

Non-Small Cell Lung Cancer

China, United States, Korea, Republic of, Canada, Poland, Taiwan, Spain, Lebanon, Malaysia, Turkey, Italy, India, Norway, Croatia, Thailand, Hong Kong, Brazil, Greece, Colombia, Bulgaria, Jordan, Romania, Serbia, Slovenia, Denmark, Vietnam, Estoni... and more

Search clinical trials for: Metastatic NSCLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations